{
    "id": 24083,
    "fullName": "RAD51 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RAD51 positive indicates the presence of the RAD51 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5888,
        "geneSymbol": "RAD51",
        "terms": [
            "RAD51",
            "BRCC5",
            "FANCR",
            "HRAD51",
            "HsRad51",
            "HsT16930",
            "MRMV2",
            "RAD51A",
            "RECA"
        ]
    },
    "variant": "positive",
    "createDate": "07/08/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7268,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IBR2 inhibited Rad52 function and induced apoptosis in a panel of cancer cell lines in culture (PMID: 23341130).",
            "molecularProfile": {
                "id": 24813,
                "profileName": "RAD51 positive"
            },
            "therapy": {
                "id": 4429,
                "therapyName": "IBR2",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6267,
                    "pubMedId": 23341130,
                    "title": "A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23341130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7269,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IBR2 inhibited Rad51 function and induced apoptosis in transformed cells over expressing BCR-ABL1 T315I in culture (PMID: 23341130).",
            "molecularProfile": {
                "id": 24816,
                "profileName": "BCR - ABL1 ABL1 T315I RAD51 pos"
            },
            "therapy": {
                "id": 4429,
                "therapyName": "IBR2",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6267,
                    "pubMedId": 23341130,
                    "title": "A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23341130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24813,
            "profileName": "RAD51 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24816,
            "profileName": "BCR - ABL1 ABL1 T315I RAD51 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}